Mangalam Drugs & Organics Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 938.36 million compared to INR 886.87 million a year ago. Revenue was INR 1,018.78 million compared to INR 899.55 million a year ago. Net income was INR 40.22 million compared to INR 64.34 million a year ago. Basic earnings per share from continuing operations was INR 2.54 compared to INR 4.07 a year ago. Diluted earnings per share from continuing operations was INR 2.54 compared to INR 4.07 a year ago.
For the nine months, sales was INR 3,128.17 million compared to INR 2,893.54 million a year ago. Revenue was INR 3,302.02 million compared to INR 2,919.6 million a year ago. Net income was INR 129.66 million compared to INR 258.17 million a year ago. Basic earnings per share from continuing operations was INR 8.19 compared to INR 16.31 a year ago. Diluted earnings per share from continuing operations was INR 8.19 compared to INR 16.31 a year ago.